Stage III Cutaneous Melanoma AJCC v7 Unknown Status Phase 1 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)Unknown Status1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02097225
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment